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Available online 13 February 2016Tumor indoleamine 2,3-dioxygenase (IDO) promotes immunosuppression by direct action on effector T cells and
Tregs and through recruitment, expansion and activation of myeloid-derived suppressor cells (MDSCs).
Targeting of MDSCs is clinically being explored as a therapeutic strategy, though optimal targeting strategies
and biomarkers predictive of response are presently unknown. Maturation and tumor recruitment of MDSCs
are dependent on signaling through the receptor tyrosine kinase CSF-1R on myeloid cells. Here, we show that
MDSCs are the critical cell population in IDO-expressing B16 tumors in mediating accelerated tumor outgrowth
and resistance to immunotherapy. Using a clinically relevant drug, we show that inhibition of CSF-1R signaling
can functionally block tumor-inﬁltrating MDSCs and enhance anti-tumor T cell responses. Furthermore,
inhibition of CSF-1R sensitizes IDO-expressing tumors to immunotherapy with T cell checkpoint blockade, and
combination of CSF-1R blockade with IDO inhibitors potently elicits tumor regression. These ﬁndings provide
evidence for a critical and functional role for MDSCs on the in vivo outcome of IDO-expressing tumors.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Recent developments in cancer immunotherapies have demonstrat-
ed durable responses, suggesting that effective immunotherapy would
hold promise to improve patient outcome (Gunturu et al., 2013; Hodi
et al., 2003; Lutz et al., 2011; Ribas et al., 2009). However, attempts to
use immunotherapeutics as single agents have achieved only limited
clinical success (Hodi et al., 2010; Le et al., 2013; Phan et al., 2003;
Robert et al., 2011; Royal et al., 2010). The resistance to immunotherapy
is in part mediated by the immunosuppressive microenvironment
in the tumor tissue, and identiﬁcation of such mechanisms is highly
prudent in order to develop appropriate combination strategies. Multi-
ple suppressive mechanisms have been implicated in the resistance
to checkpoint blockade, including accumulation of myeloid-derived
suppressor cells (MDSCs) and increased expression of indoleamine
2,3-dioxygenase (IDO).ncer Center, 1275 York Avenue,
. This is an open access article underMDSCs use severalmechanisms to induce immunosuppression, such
as production of arginase I (Arg1) and inducible nitric oxide synthase
(iNOS), leading to T-cell inhibition (Gabrilovich and Nagaraj, 2009).
MDSCs can also promote tumor cell proliferation, confer resistance
to cytotoxic therapies, and facilitate metastatic dissemination and
angiogenesis (Gabrilovich and Nagaraj, 2009). Therefore, high numbers
of tumor-inﬁltrating MDSCs are often associated with high tumor
burden and metastatic disease, leading to poor survival in cancer
patients (Diaz-Montero et al., 2009). Therapeutic targeting of MDSCs
might overcome immunosuppression to enhance responses to
immunotherapy.
Targeting of the colony stimulating factor-1 receptor (CSF-1R) has
emerged as a strategy to ablate MDSCs or inhibit their tumor-
promoting functions (Manthey et al., 2009; Patel and Player, 2009).
CSF-1 is a cytokine frequently produced by several cancers, including
melanoma, pancreatic cancer, and breast cancer (Priceman et al.,
2010; Richardsen et al., 2015; Tarhini et al., 2012; Zhu et al., 2014). Se-
creted CSF-1 binds to the tyrosine kinase receptor CSF-1R on myeloid
cells, which results in increased proliferation and differentiation of
myeloid cells into MDSCs and M2 macrophages, and their recruitment
into tumors (Caescu et al., 2015; Dai et al., 2002).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ated by CSF-1 may limit the anti-tumor activity of tumor immunother-
apy and lead to low response rates (Kerkar andRestifo, 2012). PLX647 is
an analog of PLX3397, which is a potent CSF-1R inhibitor currently in
clinical development as a single agent and in combination for the treat-
ment of cancer patients. Recent work in preclinical models shows that
CSF-1R inhibition inhibits the immunosuppressive tumor microenvi-
ronment and facilitates immune responses to cancer (Aharinejad
et al., 2004; Coniglio et al., 2012; DeNardo et al., 2011; Mok et al.,
2014; Priceman et al., 2010; Xu et al., 2013).
Despite these ﬁndings, its relation with known suppressive mecha-
nisms is unclear and what biomarkers would predict sensitivity
to CSF-1R inhibition is not well deﬁned. Here, we examine the possibil-
ity of circumventing IDO suppression by targeting MDSCs in IDO-
expressing tumors. Indeed, while studying the role of IDO in the
tumor microenvironment, we previously found that overexpression of
IDO by tumor cells (B16-IDO) promotes the recruitment of large num-
bers of highly suppressive MDSCs (Holmgaard et al., 2015). We took
advantage of this tumor model to examine the possibility of abolishing
the suppressive effect of IDO by targeting MDSCs in IDO-expressing tu-
mors. We studied the role of the MDSCs in mediating resistance to im-
munotherapies and to develop rationally designed combinatorial
immunotherapeutic approaches through CSF-1R targeting. Our data
demonstrate that CSF-1R blockade with PLX647 depletes suppressive
MDSCs and delays tumor growth in the B16-IDO tumormodel dominat-
ed byMDSCs, but not in the control B16 tumormodel. Inhibition of CSF-
1R signaling functionally blocks MDSCs and enhances anti-tumor T cell
responses and therefore partially rescue immune suppression conferred
by IDO expression. Thus, our data demonstrate a reversal of IDO induced
immunosuppression by targeting MDSCs through CSF-1R blockade.
Moreover, we demonstrate that targeting of CSF-1R sensitized the tu-
mors to immunotherapy with Cytotoxic T Lymphocyte-Associated
Protein-4 (CTLA-4), Programmed Cell Death Protein-1 (PD-1), or IDO
blockade. Previous work suggests that IDO promotes immune suppres-
sion by direct action on effector T cells and/or regulatory T cells (Tregs).
Our ﬁndings suggest that both T cells andMDSCs contribute to IDO sup-
pressive effects and as a result provide a strong rationale to reprogram
immunosuppressive MDSCs in the tumor microenvironment under
conditions that can signiﬁcantly improve the effects of other immuno-
therapeutic agents that target T cells and IDO. Supporting theseﬁndings,
we ﬁnd that CSF-1R blockade also potentiates antitumor responses to T
cell checkpoint immunotherapy in other animal tumor models. Impor-
tantly, this potentiation was only seen in tumors highly inﬁltrated
with suppressive MDSCs, suggesting that the presence of MDSCs could
serve as a pre-treatment biomarker that could predict the efﬁcacy of
such combination in patients.
2. Materials and Methods
2.1. Mice
C57BL/6J and Balb/c mice (6–8 weeks old) were purchased from
Jackson Laboratory. Pmel-1 TCR transgenic mice have been reported
(Overwijk et al., 2003) andwere providedbyN. Restifo (National Cancer
Institute, Bethesda, MD). All mice were maintained in microisolator
cages and treated in accordancewith the NIH and American Association
of Laboratory Animal Care regulations. Allmouse procedures and exper-
iments for this study were approved by the Memorial Sloan Kettering
Cancer Center Institutional Animal Care and Use Committee.
2.2. Cell Lines
The murine cancer cell line for melanoma (B16F10, referred to
as B16) and colon cancer (CT26) were maintained in RPMI medium
supplementedwith 10% fetal calf serum (FCS) and penicillin with strep-
tomycin (complete RPMI media). The Flt3L-secreting B16 cell line wasused to increase the number of APCs recruited to the spleen before
puriﬁcation of dendritic cells (DCs) (Curran and Allison, 2009).
2.3. Transduction of B16 Cells
B16-IDO was generated by transduction of B16F10 with GFP plus
the IDO gene as previously described (Holmgaard et al., 2013). Brieﬂy,
GFP-tagged murine IDO cDNA (Origene Technologies) was cloned into
the pMDG lentiviral vector. Recombinant virus production and infection
of target cells were done as described (Diatta et al., 2005). B16F10
transduced with GFP alone were used as control cells (B16-WT).
2.4. Tumor Challenge and Treatment Experiments
On day 0 of the experiments, tumor cells were injected intradermal-
ly (i.d.) in the right ﬂank. For the B16 model, 2.5 × 105 B16-WT or B16-
IDO cells were injected into C57BL/6J mice and for the CT26 model,
5 × 105 CT26 cells were used in Balb/c mice. Treatments were given as
single agents or in combinations with the following regimen for each
drug. The IDO inhibitor drug indoximod/D-1MT (IDOi) was either
dissolved in methylcellulose and administered in drinking water
(2 mg/ml, mice drank 4.5–5.5 ml/day, Sigma-Aldrich) or formulated
and administered in implantable subcutaneous pellets (140 mg/pellet,
14-day-release, Innovative Research of America). Treatment with IDOi
was initiated on day 1 ending on day 15 post tumor challenge. Control
groups received placebo pellets without the active product (Innovative
Research of America). Anti-CTLA-4 antibody (100 μg/mouse, clone
9H10, Bio X cell) and anti-PD-1 antibody (250 μg/mouse, clone RPM1-
14, Bio X cell) were injected intraperitoneally (i.p.) on days 3, 6 and 9
for the B16model and on days 10, 13 and 16 for the CT26model. Control
groups received a corresponding dose of isotype antibody i.p. The CSF-
1R kinase inhibitors, PLX647 and PLX5622 incorporated into rodent
chow, were provided along with control chow by Plexxikon Inc.
(800 ppm chow). Treatment with PLX647 or control chows was started
at day 0 for the B16 model and on day 10 for the CT26 model, and con-
tinued for the remainder of the experiment. For in vivo T cell depletion
experiments, mice were injected i.p. with 500 μg of monoclonal anti-
bodies to CD8 (clone 2.43) or CD4 (clone GK1.5), 1 day before and
2 days after tumor challenge, followed by injection of 250 μg every
5 days throughout the experiment. The efﬁcacy of cell depletion was
veriﬁed by staining peripheral blood leukocytes for speciﬁc subsets
after depletion. Tumors were measured every second or third day
with a caliper, and the volume (length × width × height) was calculat-
ed. The animals were euthanized for signs of distress or when the total
tumor volume reached 1000 mm3.
2.5. Isolation of Tumor-inﬁltrating Cells and Lymphoid Tissue Cells
Mouse tumor samplesweremincedwith scissors prior to incubation
with 1.67 U/ml Liberase (Roche) and 0.2 mg/ml DNase (Roche) in RPMI
for 30 min at 37 °C. Tumor samples were homogenized by repeated
pipetting and ﬁltered through a 100-μm nylon ﬁlter (BD Biosciences)
in RPMI supplemented with 7.5% FCS to generate single-cell suspen-
sions. Cell suspensions were washed once with complete RPMI and pu-
riﬁed on a Ficoll gradient to eliminate dead cells. Cells from mouse
spleens were isolated by grinding spleens through 100-μm ﬁlters.
After red blood cell (RBC) lysis (ACK Lysing Buffer, Lonza) when re-
quired, all samples were washed and re-suspended in FACS buffer
(PBS/2%FCS).
2.6. Flow Cytometry and Morphology Analysis
Cells isolated from mouse tumors and spleens were pre-incubated
(15 min, 4 °C) with anti-CD16/32 monoclonal antibody (Fc block, clone
2.4G, BD Biosciences) to block nonspeciﬁc binding and then stained
(30 min, 4 °C) with appropriate dilutions of various combinations of the
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(clone 17A2), anti-MHC Class II-eFluor 450 (clone M5/114.15.2), anti-
CXCR3-PE (clone CXCR3-173), anti-CSF-1R-PE (clone AFS98), anti-
CXCR3 (clone CXCR3-173), anti-CTLA-4-PE (clone UC10-4B9), anti-CD8-
PE Texas Red (clone 5H10), anti-Gr1-PerCP-Cy5.5 (clone R86-8C5),
anti-CD4-PE-Cy7 (clone RM4-5), anti-Granzyme B-PE-Cy7 (clone
NGZB), anti-PD-1-PE-Cy7 (clone J43), anti-CD45-APC (clone 104), anti-
F4/80-APC (clone BM8), anti-Foxp3-Alexa Fluor 700 (clone FJK-16S),
anti-CD11c-Alexa Fluor 700 (clone N418), and anti-CD11b-APC eFluor
780 (clone M1/70) antibodies, all purchased from BD Biosciences,
eBioscience or Invitrogen. The cells were further permeabilized using a
FoxP3 Fixation and Permeabilization Kit (eBioscience) and stained for
Foxp3 (clone FJK-16s, Alexa-Fluor-700-conjugated, eBioscience) and
Ki67 (clone SolA15, eFluor-450-conjugated, eBioscience). The stained
cells were acquired on a LSRII Flow Cytometer using BD FACSDiva soft-
ware (BD Biosciences) and the data were processed using FlowJo soft-
ware (Treestar). Dead cells and doublets were excluded on the basis of
forward and side scatter.
2.7. DC Puriﬁcation and Loading
Micewere injected subcutaneously with 2 × 106 Flt3L-secreting B16
cells and sacriﬁced after 2 weeks. Spleenswere digested with 1.67 U/ml
Liberase (Roche) and 0.2 mg/ml DNase (Roche) in RPMI for 30 min
at 37 °C. Samples were ﬁltered through a 100-μm nylon ﬁlter (BD
Biosciences) and puriﬁed on a Ficoll gradient, before positive selection
of CD11c+DCs according to themanufacturer's instructions (Miltenyi).
DCs were cultured overnight with 10 ng/ml recombinant GM-CSF
(PeproTech) and B16 tumor lysate in a 4:1 ratio of dead tumor cells to
DCs. After loading, DCs were puriﬁed by Ficoll gradient (Sigma).
2.8. Tumor Lysate
Tumor cell lysate was prepared by radiation (140 Gy) followed by 5
rounds of freezing and thawing to lyse the tumor cells. Nuclear debris
was removed by centrifugation. Cell lysate was ﬁltered and cell death
was veriﬁed using Trypan blue dye exclusion.
2.9. T Cell Assays
For cytokine production, tumor-inﬁltrating lymphocytes (TILs) were
incubated overnight with DCs loaded with tumor lysate and 20 U/ml
IL-2 (PeproTech). Brefeldin A (BD Biosciences) at 10 μg/ml was added
for the last 4–5 h of stimulation. After in vitro stimulation, TILs
were stained for intracellular cytokines with a FoxP3 Fixation and
Permeabilization Kit (eBioscience) using antibody to anti-IFNγ-FITC
(clone XMG1.2).
2.10. Puriﬁcation of MDSCs
Mouse tumor and spleen single-cell suspensions were generated as
described in the previous section. Tumor cells were subsequently sepa-
rated from debris over a Ficoll gradient (Sigma-Aldrich). B cells were
depleted from splenocytes using CD19 microbeads and LD columns ac-
cording to the manufacturer's instructions (Miltenyi Biotec) to enrich
the myeloid fractions. Cells were stained with anti-CD45.2-Alexa-
Fluor-700, anti-CD11b-APC-Cy7 and anti-Gr1-PerCP-Cy5.5 antibodies
for ﬂow sorting on a FACSAria™ II Cell Sorter (BD Biosciences). Dead
cells were excluded using DAPI (Invitrogen). Purity of ﬂow-sorted
populations was above 90%.
2.11. T cell Suppression Assay with MDSCs
Spleens and lymph nodes fromnaivemicewere isolated and ground
through 100-μm ﬁlters to generate a single cell suspension. After RBC
lysis, CD8+ cells were puriﬁed using anti-CD8 (Ly-2) microbeads(Miltenyi Biotech) according to manufacturer's protocol and labeled
with 1 mM CFSE (Invitrogen) in pre-warmed PBS for 10 min at 37 °C.
The CFSE-labeled CD8+ T cells were then plated in complete RPMI
media supplemented with 0.05 M β-mercaptoethanol onto round bot-
tom 96-well plates (1 × 105 cells per well) coated with 1 μg/ml anti-
CD3 (clone 1454-2C11) and 5 μg/ml anti-CD28 (clone 37N) antibodies.
PuriﬁedMDSCswere added in indicated ratios and plates were incubat-
ed at 37 °C. After 48 h, cells were harvested and CFSE signal in the gated
CD8+ T cells was measured by ﬂow cytometry (LSRII Flow Cytometer,
BD Biosciences).
2.12. Isolation of Pmel Lymphocytes and Adoptive Transfer
Spleens and lymph nodes from pmel-1 TCR transgenic mice were
isolated and ground through 100-μm ﬁlters. After RBC lysis, CD8+ cells
were puriﬁed by positive selection using Miltenyi magnetic beads. The
isolated cells were loaded with CellTrace™ Far Red DDAO-SE (Thermo
Fisher Scientiﬁc) and injected into recipient animals via tail vein at
indicated numbers. Activated CD8+ T cells were generated by
culturing splenocytes with soluble anti-CD3 (1 μg/ml, clone 145-2C11,
eBioscience) and anti-CD28 (2 μg/ml, clone 37.51, eBioscience) for
72 h. Recombinant mouse IL-2 (30 U/ml, Chiron) was added for the
ﬁnal 24 h of culture. CD8+ T cells were subsequently positively selected
with Miltenyi magnetic beads prior to injection via tail vein, as de-
scribed above. The frequency and proliferation of pmel cells were mea-
sured 2 weeks after tumor challenge and 7 days after adoptive transfer
of 1 × 106 in vitro activated CD8+pmel T cells using Thy1.1 antibody and
by assessing CellTrace™ Far Red DDAO-SE dilution by ﬂow cytometry,
respectively.
2.13. Statistics
Where indicated, data were analyzed for statistical signiﬁcance and
reported as P values. Data were analyzed by 2-tailed Student's t test
when comparing means of two independent groups and two-way
ANOVA when comparing more than two groups. P b 0.05 was consid-
ered statistically signiﬁcant (*P b 0.05, **P b 0.01, ***P b 0.001,
****P b 0.0001). Evaluation of survival patterns in tumor-bearing mice
was performed by the Kaplan–Meier method, and results were ranked
according to the Mantel–Cox log-rank test. P b 0.05 was considered sta-
tistically signiﬁcant (*P b 0.05, **P b 0.01, ***P b 0.001, ****P b 0.0001).
Survival was deﬁned as mice with tumors b1.000 cm3.
3. Results
3.1. Expression of IDO by Tumors Results in Recruitment of CSF-1R Expressing
MDSCs
Aswe have previously reported (Holmgaard et al., 2015), expression
of IDO by tumor cells (B16-IDO) results in expansion of myeloid
CD11b+ cells in the tumor and spleen (Fig. 1a), which is dominated
by an increase in frequencies of monocytic CD11b+Gr1int cells
(Fig. 1b). The CD11b+Gr1int cells puriﬁed from B16-IDO tumors sup-
press CD8 T cell proliferation in vitro, consistent with their functional
deﬁnition of MDSCs (Fig. 1c). Furthermore, these tumors were resistant
to immunotherapy with CTLA-4 + PD-1 blockade, when compared to
the wild type B16 tumors (B16-WT) (Fig. 1d). To determine whether
the MDSCs were primary mediators of suppression and to develop ap-
propriate strategies to block them, we focused on CSF-1R, which has
been previously shown to play a role in MDSC development (Dai et al.,
2002; Li et al., 2006). Phenotypic analysis of the Gr1 positive popula-
tions revealed that CD11b+Gr1int cells, but not CD11b+Gr1high cells,
from tumors and spleens of B16-IDO tumor-bearing mice express high
levels of CSF-1R (Fig. 1e). On the basis of these observations, we
proceeded to determine the role of CSF-1R in our tumor model.
Fig. 1. IDO positive tumors show increased inﬁltration of CSF-1R expressingMDSCs. (a) B16-IDO and B16-WT tumors and spleenswere harvested 2weeks after tumor cell inoculation and
analyzed for inﬁltration with MDSC subsets. Results are shown for total myeloid cells (CD11b+) as frequencies of CD45+ cells. (b) Frequencies of CD11b+Gr1high and CD11b+Gr1int
subsets of total CD45+ TILs and CD45+splenocytes. (c) In vitro suppressive activity of tumor-inﬁltrating CD11b+Gr1int cells puriﬁed from B16-IDO tumor-bearing mice. Percent CD8+
T cell proliferation (left panel) and representative histograms of CD8+ T cell proliferation in CD11b+ to CD8+ T cell ratio of 1:1 (right panel). (d) Long-term survival of anti-CTLA-
4 + PD-1 treated B16-IDO and B16-WT tumor-bearing mice. (e) Expression of CSF-1R in Gr1int and Gr1high cells within the CD11b+gated population of TILs and splenocytes of B16-
IDO tumor-bearing mice. Data depicted are mean ± SEM from 3 independent experiments with 5–10 mice/group.
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High MDSC Inﬁltration by Depletion of Suppressive CD11b+Gr1int MDSCs
Several compounds have been developed to speciﬁcally target CSF-
1R. PLX647 is a small molecule receptor tyrosine kinase inhibitor
inhibiting signaling from CSF-1R and KIT (Elmore et al., 2014; Zhang
et al., 2013). To study the effects of PLX647 on B16-IDO tumors, mice
were challenged with B16-IDO tumor cells and treated with PLX647
chow. In order to understand the impact of CSF-1R blockade on Gr1
subsets, we compared the composition of Gr1+ cell populations from
B16-IDO tumors following a 2-week treatment with either PLX647 or
control chow. PLX647 treatment resulted in a signiﬁcant reduction in
the number of CSF-1R expressing CD11b+Gr1int cells in the spleens,
tumor-draining lymph nodes (TDLNs), and tumors of B16-IDO tumor-
bearing mice (Fig. 2a), which was the population that we found to be
suppressive in the functional assays (Fig. 1c). In contrast, the CSF-1Rnon-expressing granulocytic CD11b+Gr1high population was not affect-
ed by PLX647 therapy (Fig. 2a). Consistent with these results, PLX647
treatment caused a delay in B16-IDO tumor growth and resulted in
prolonged long-term survival (Fig. 2b). At day 14, the mean weight of
B16-IDO tumors was three times smaller in the MDSC-depleted mice
compared to mice treated with control chow (Fig. 2c). In contrast,
B16-WT tumors, which exhibit signiﬁcantly lower numbers of tumor-
inﬁltrating CD11b+Gr1int cells did not respond to PLX647 treatment
(Fig. 2b). As PLX647 is a selective bispeciﬁc inhibitor of CSF-1R and
KIT receptor tyrosine kinases (Elmore et al., 2014; Zhang et al., 2013),
we performed a similar experiment with another CSF-1R inhibitor,
PLX5622, which has a higher speciﬁcity for CSF-1R (Cavnar et al.,
2013; Kim et al., 2014) in order to verify that the observed anti-tumor
effect of PLX647 in the B16-IDO tumor model was mediated by inhibi-
tion of CSF-1R and not inhibition of KIT kinases. Therapeutic anti-
tumor effects of PLX5622 and PLX647were equivalent (Fig. 2d), further
Fig. 2. CSF-1R blockade inhibits tumor growth of tumors with high MDSC inﬁltration by depletion of CD11b+Gr1int MDSC subsets. (a) Mice were injected with B16-IDO tumor cells and
treated with PLX647 or control chow. Frequencies of Grhigh and Grint cell subsets of total CD11b+ cells in the spleen, LN, TDLN, and tumor after 2 week treatment with PLX647 or control
chow, and representative ﬂow plots of CD11b+Gr1high and CD11b+Gr1int cell populations of CD45+ cell gated TILs after treatment with PLX647 or control chow. (b) Survival and tumor
growth inmice injectedwith B16-IDO or B16-WT tumor cells and treatedwith PLX647or control chow. (c) Tumorweights. (d)Mean tumor growth andoverall survival of B16-IDO tumor-
bearing mice treated with PLX647, PLX5622 or control chow. Data shown are mean ± SEM of 3 independent experiments.
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ﬁndings indicate that PLX647 speciﬁcally depletes CSF-1R-expressing
MDSC subsets in the B16 tumormodel and that pre-treatment presence
of high levels of suppressive MDSCs is a predictive anti-tumor effect.Fig. 3. CSF-1R blockade increases antigen-speciﬁc T cell activity at the tumor site. (a)Micewere
tumor challengemice adoptively received in vitro activated pmel CD8+ T cells andwere sacriﬁc
cells of total CD8+ T cells in LN, TDLN, and tumors in each group ofmice are shown. (b) B16-IDO
treatmentwith PLX647 or control chow. (c) Expression of CXCR3, Ki-67 andGranzyme B on tum
(d) Percentage tumor-inﬁltrating CD8+ pmel T cells frommice treated with PLX647 or control
mean ± SEM of 3 independent experiments.3.3. CSF1R Blockade Increases Anti-tumor T Cell Activity at the Tumor Site
To speciﬁcally evaluate the impact of CD11b+Gr1int MDSC depletion
on the tumor-speciﬁc immune responses, B16-IDO tumor-bearingmiceinjectedwith B16-IDO tumor cells and treatedwith PLX647 or control chow. Five days after
ed 2weeks after tumor challenge. Average percentage and representative dot plots of pmel
tumor size inmice after adoptive transfer of increasing numbers of CD8+pmel T cells and
or-inﬁltrating CD8+ pmel T cells isolated frommice treatedwith PLX647 or control chow.
chow expressing PD-1 and CTLA-4 and representative ﬂow histograms. Data are shown as
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pmel CD8+ T cells, which express transgenic T cell receptor recognizing
melanoma gp100 antigen. Importantly, depletion of CD11b+Gr1int cells
with PLX647 resulted in signiﬁcantly greater accumulation of pmel T
cells at the tumor site and draining lymph nodes (Fig. 3a). This was
accompanied by signiﬁcant delay in tumor growth, which was most
pronounced with the highest pmel dose, underscoring the active role
of antigen-speciﬁc immunity mediating the anti-tumor effect (Fig. 3b).
Furthermore, phenotypic characterization of pmel T cells from tumors
of mice receiving PLX647 treatment demonstrated up-regulation of
GranzymeB (GrB) andKi-67, and a non-statistically-signiﬁcant increase
in CXCR3, over the untreated mice further indicating that the tumor-
inﬁltrating pmel cells acquire cytotoxic phenotype (Fig. 3c).
3.4. CSF-1R blockade Potentiates the Anti-tumor Efﬁcacy of T Cell Checkpoint
Immunotherapy
As noted above, treatment with CSF-1R inhibitor alone was able
to delay the tumor growth, however all of the tumors eventually
grew out, resulting in only modest beneﬁt on overall survival (Fig. 2b).
Recently, it was reported that while CSF-1/CSF-1R blockade
reprogrammed the tumor microenvironment to enhance effector T
cell inﬁltration in pancreatic tumors, upregulation of T cell checkpoints
was also enhanced (Zhu et al., 2014). Similarly, we observed that CTLA-
4 expression on tumor-inﬁltrating CD8+ pmel cytotoxic T lymphocytes
(CTLs) was signiﬁcantly upregulated by CSF-1R blockade (Fig. 3d). In
addition, activated pmel CTLs in the B16-IDO tumors showed high levels
of PD-1 expression (Fig. 3d), although unaffected by CSF-1R blockade
(Fig. 3d). These data suggest that although CSF-1R blockade enhances
T cell inﬁltration in B16-IDO tumors, the anti-tumor immunity may be
limited via constitutive expression or upregulation of T cell checkpoints.
Therefore, we hypothesized that CSF-1R blockade could enhance B16-
IDO tumor responses to CTLA-4 and PD-1 blockade. To test this hypoth-
esis, B16-IDO tumor-bearing mice were treated with PLX647 in combi-
nation with anti-CTLA-4 and anti-PD-1 antibodies. Anti-CTLA-4 + anti-
PD-1 checkpoint alone had only very limited efﬁcacy on the progression
of B16-IDO tumors with no effect on overall survival (Fig. 4a). By con-
trast, the combination of PLX647 with anti-CTLA-4 + anti-PD-1Fig. 4. CSF-1R blockade potentiates antitumor responses to checkpoint blockade. (a)Mean tumo
aCTLA-4+ aPD-1. (b) B16-IDO tumors frommice treatedwith PLX647 and/or aCTLA-4+ aPD-1
CD45+ cells and T cells per gram of tumor. (c) Inﬁltration of CD8+ T cells, CD4+Foxp3− T ce
showing IFNγ expressing CD8+ T cells in response to in vitro stimulation with DCs. (e) Effe
CD11b+Gr1int subsets of CD45+ TILs. (g) Survival curves for B16-IDO tumor-bearing mice tre
a corresponding dose of IgG isotype control. (h) Mean tumor growth and overall survival
mean ± SEM of 3 independent experiments with 5 mice/group.antibodies signiﬁcantly reduced tumor progression and enhanced over-
all survival, when compared to untreated mice and mice treated with
PLX647 or CTLA-4 + PD-1 antibodies alone (Fig. 4a). Analysis of T cell
responses in tumors following combined therapy with PLX647 and
anti-CTLA-4 + anti-PD-1 antibodies revealed a signiﬁcant increase in
numbers of CD45+ cells and T cells in the combination therapy group
(Fig. 4b). This increase in tumor inﬁltrating lymphocytes (TILs) was pri-
marily due to inﬁltration of IFNγ+CD8+ and CD4+ effector T cells but
not Treg cells (Fig. 4c and d), leading to favorable effector to Treg ratios
(Fig. 4e). The increase in number of T cells was accompanied by a de-
crease in CD11b+Gr1int MDSCs following the combined therapeutic
regimen (Fig. 4f). To determine if tumor responses in PLX647 treated
mice were dependent on T cells, we conducted CD4 and CD8 T cell de-
pletion studies. Depletion of CD4 as well as CD8 T cells signiﬁcantly re-
duced the therapeutic effect of anti-CTLA-4 + anti-PD-1 antibodies
(Fig. 4g), suggesting that CSF-1R blockade improves immunotherapy
with immunomodulatory antibodies by enhancing T cell activities
through depletion of CD11b+Gr1int MDSCs from the tumor microenvi-
ronment. This enhancement, however, was only evident in the B16-
IDO tumormodel, whichpossesses high levels ofMDSCs, butwas absent
in the B16-WT tumor model (data not shown).
3.5. Combination Therapy with CSF-1R and T Cell Checkpoint Blockade is
Effective Against Established Colon Tumors
To determine whether the CSF-1R + T cell checkpoint blockade
treatment strategy could be extended to other tumor types, we evaluat-
ed it in the CT26 colorectal carcinoma model, where expansion of
MDSCs has previously been described (Dolcetti et al., 2010; Youn
et al., 2008). To this end, BALB/c mice were challenged with CT26
tumor cells and treatment with PLX647 and/or anti-CTLA-4 + PD-1
was initiated 10 days after tumor inoculation when tumors exhibited
a volume of approximately 50–100 mm3. The combination of dual
CSF-1R inhibition and checkpoint blockade caused a delay of tumor
growth with prolonged long-term survival in a subset of mice, whereas
the individual components had little to no effect on tumor growth
(Fig. 4h). Thus, the therapeutic activity of the combination of CSF-1R
blockade and anti-CTLA-4 + PD-1 is not restricted to the B16-IDOr growth and overall survival of B16-IDO tumor-bearingmice treatedwith PLX647 and/or
were harvested 2weeks after tumor cell inoculation and analyzed for absolute numbers of
lls and CD4+Foxp3+ Tregs gated on the CD45+ population. (d) Representative dot plots
ctor T cells to Treg ratios in tumors. (f) Relative percentage of total CD11b+ cells and
ated with PLX647 and/or aCTLA-4 + aPD-1 plus depleting antibodies for CD8 and CD4 or
of CT26 tumor-bearing mice treated with PLX647 and/or aCTLA-4 + aPD-1. Data are
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tumor model (Zhu et al., 2014).
3.6. CSF1R Blockade Potentiates the Therapeutic Effect of IDO Inhibition
The B16-IDO tumor model is characterized by high expression of
IDO, which exerts immune suppression not just through recruitment
of MDSCs, but also through additional mechanisms, which include di-
rect inhibition of effector T cells and expansion and activation of Tregs
(Munn and Mellor, 2007). We thus proceeded to examine whether de-
pletion of CD11b+Gr1int MDSCs could sensitize the tumors to IDO
inhibitor-based immunotherapy. To test this hypothesis, B16-IDO
tumor-bearing mice were treated with the IDO inhibitor, indoximod/
D-1MT (IDOi), in combination with PLX647. While the agents were
only modestly effective on their own, we observed signiﬁcant tumor
growth delay and an increase in overall survival with the combination
therapy (Fig. 5a). This reduction in tumor growth correlated with in-
creases in CD8+ and CD4+ effector T cells (Fig. 5b). Taken together,
our data show that CD11b+Gr1int MDSCs enhance tumor growth and
inhibit tumor-speciﬁc immunity in vivo, highlighting the importance
of MDSC as a therapeutic target. From a clinical perspective, these data
also suggest that CSF-1R blockade might be a relevant strategy only
for patients with tumors highly inﬁltrated with suppressive MDSCs,
suggesting that clinical studies of such compounds should include pre-
treatment evaluation of tumor MDSCs as a potential predictive
biomarker.
4. Discussion
Even though T cell checkpoint inhibitors alone have achieved
impressive clinical beneﬁt in some cancers, their application as singleFig. 5. CSF-1R blockade enhances responses to IDO blockade immunotherapy. (a) Mean tumor
IDOi. (b) B16-IDO tumors from mice treated with PLX647 and/or IDOi were harvested 2 week
Results for CD4+Foxp3+ Tregs, CD8+ and CD4+ effector T cells as percentages of total CD3+ T
mean ± SEM of 3 independent experiments with 5 mice/group (a) or one representative expeagents has had limited efﬁcacy (Hamid et al., 2013; Wolchok et al.,
2013). The resistance to immunotherapy is in part mediated by the im-
munosuppressive microenvironment in the tumor tissue, and identiﬁ-
cation of such mechanisms is highly prudent in order to develop
appropriate combination strategies.
Tumor-inﬁltrating suppressivemyeloid cells have been demonstrat-
ed to be an important component of the inhibitory tumormicroenviron-
ment and include macrophages with the M2 phenotype and MDSCs.
Depending on the tumor model; different myeloid populations may be
dominant. Reports have shown that some tumor models such as pros-
tate cancer and lung carcinoma models are dominated by MDSCs and
these MDSCs heavily inﬁltrate tumors and systemic organs such as
spleen, blood, and bone marrow (Srivastava et al., 2012; Xu et al.,
2013). In contrast, other tumor models have few MDSCs inﬁltrating
the tumor or accumulating in the spleen, and are primarily dominated
by macrophages (Mok et al., 2014; Pyonteck et al., 2013).
While studying the role of IDO in immune suppression, we found
that tumor IDO expression induces recruitment of MDSCs to tumors
in several mouse tumor models (Holmgaard et al., 2015). We thus
established an IDO-expressing tumor model which allowed for studies
of MDSC targeting in both MDSC-high and MDSC-low tumor types.
Here we ﬁnd high expression of CSF-1R on the dominant suppressive
subset of MDSCs in B16-IDO tumors. Our data demonstrate that CSF-
1R blockade with PLX647 decreases the quantity of MDSCs in B16-IDO
tumors, leading to increased anti-tumor immunity. The blockade alone
modestly enhances antitumor responses, promotes CTL inﬁltration,
and slows tumor progression. However, the therapeutic effect of such
inhibition is limited and does not induce tumor regression. Although
CSF-1R blockade enhances the anti-tumor activity of myeloid cells and
T cell responses, we found that its efﬁcacy was blunted by high expres-
sion and upregulation of immune checkpoint molecules, which wasgrowth and overall survival of B16-IDO tumor-bearing mice treated with PLX647 and/or
s after tumor cell inoculation and analyzed for inﬁltration of various immune cell subsets.
cells, and Gr1int MDSCs as percentages of total CD11b+ cells are shown. Data shown are
riment of 2 (b).
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tumormodel. Inhibition of CSF-1R, however, markedly improved the ef-
ﬁcacy of checkpoint- and IDO-based immunotherapy and led to regres-
sion of established tumors. The antitumor activity of a combined
therapy with CSF-1R and T cell checkpoint blockade was mediated by
inhibition of the myeloid cell-mediated immunosuppressive tumor mi-
croenvironment, resulting in increased tumor inﬁltrationwith activated
T cells. These studies thus suggest that the resistance to immune check-
point blockade could be alleviated by therapeutic strategies that repro-
gram dominant myeloid responses to allow for effective checkpoint
therapy. To this end, our group has shown that pre-treatment levels of
circulating MDSCs can predict therapeutic outcomes from CTLA-4
blockade in melanoma patients (Kitano et al., 2014). The ﬁndings
above were not only restricted to the B16-IDO model, but were also
noted in established CT26 colon tumors.
While the IDO inhibitor therapy synergized with CSF-1R blockade
in the B16-IDO tumor model, it was not as effective as the synergy
between T cell checkpoint blockade and CSF-1R blockade. Tumor inﬁl-
tration ofMDSCsmight be a result of high levels of IDO expression as re-
cently published (Holmgaard et al., 2015), and thus, IDO inhibitors and
CSF-1R blockade potentially target the same immunepathway,whereas
the T cell checkpoint blockade and CSF-1R blockade therapies act on
different immune components and pathways.
Several preclinical studies have suggested that inhibition of CSF-1R
signaling may alter the immunologic response of tumor-inﬁltrating
MDSCs and/or tumor-inﬁltrating macrophages (DeNardo et al., 2011;
Mitchem et al., 2013; Mok et al., 2014; Priceman et al., 2010; Pyonteck
et al., 2013; Sluijter et al., 2014; Strachan et al., 2013; Xu et al., 2013;
Zhu et al., 2014). Mok et al. (2014) targeted CSF-1R signaling using
PLX3397 in a murine SM1 melanoma model. PLX3397 treatment de-
pleted more than 80% of tumor-inﬁltrating macrophages, leading to an
increased efﬁcacy of adoptively transferred T cell based therapies.
Other studies have shown that CSF-1R blockade therapy reduced the
number ofMDSCs aswell asmacrophages in tumor and systemic organs
(Priceman et al., 2010; Xu et al., 2013). Using the selective inhibitor of
CSF-1R, GW2580, Priceman et al. (2010) demonstrated that CSR-1R
signaling regulated recruitment of both MDSCs and M2 macrophages
to lung, melanoma, and prostate tumors.
In our model, CSF-1R blockade with PLX647 mainly targeted the
more abundant MDSCs instead of macrophages, suggesting that the
role of CSF-1 may be tumor model-dependent. Different tumor models,
genetic backgrounds, or treatmentsmay induce different growth factors
or cytokines in the tumormicroenvironment. Inﬁltration and differenti-
ation of myeloid cells in tumors is a complex process regulated by mul-
tiple pathways, which may lead to differential responses to CSF-1R
inhibition (Li et al., 2009; Lin et al., 2008; Sawanobori et al., 2008; Wei
et al., 2010). For example, while CSF-1R inhibition in pancreas melano-
ma and breast models resulted in reduction of macrophage numbers,
in amurine gliomamodel Pyonteck et al. (2013) have shown that block-
ade of CSF-1R signaling using the small molecule inhibitor BLZ945,
favorably reprograms macrophage responses without reducing
their numbers. In that study, CSF-1R blockade impaired the tumor-
promoting functions of M2 macrophages and led to regression of
established tumors. Taken together, these results suggest that CSF-1R
signaling can regulate both the number and function of tumor-
inﬁltrating myeloid cells, but these activities may be highly dependent
on the tumor type or tissue-speciﬁc factors.
Finally, by being able to study both MDSC-high and MDSC-low
tumormodels, we were able to evaluate the rationale for CSF-1R inhibi-
tion in both types of tumors. Perhaps not surprisingly, our results sug-
gest that the efﬁcacy of CSF-1R blockade is limited to tumors with
high inﬁltration of CSF-1R expressing suppressive cells. As CSF-1R inhib-
itors are entering immunotherapy clinical trials, it will be important to
evaluate tumor-inﬁltrating MDSCs and macrophages as a mechanism
of resistance to immune checkpoint blockade and as a potential bio-
marker that could predict responses to CSF-1R inhibition.In conclusion, we describe that blockade of CSF-1R signaling in B16-
IDO tumors depletes CD11b+Gr1int MDSCs and reprograms the tumor
microenvironment to support antitumor immunity. By decreasing the
presence of immunosuppressive CD11b+Gr1int MDSCs in the tumor,
PLX647 likely facilitates the intratumoral trafﬁcking of CTLs and their
antitumor functions. Furthermore, our studies suggest that MDSC inhi-
bition alone by PLX647 is not sufﬁcient for an efﬁcient antitumor re-
sponse in the B16-IDO tumor model. An active T cell-mediated
immunotherapy is needed for an optimal antitumor effect of PLX647
and thus, the main beneﬁcial effects of PLX647 in the B16-IDO model
may be derived from the ability to improve T cell effector functions
through the inhibition of intratumoral immunosuppressive MDSCs.
These data suggest that CSF-1R may be an effective therapeutic target
to reprogram the immunosuppressive microenvironment of human
tumors strongly inﬁltrated with myeloid cells and provide a strong ra-
tionale for the development of new therapeutic approaches targeting
CSF-1R in combination with other agents.
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